You are here: Industry Insights > Press Release

News List

FDA-approved drug effectively treats rare chronic immune disorder firstwordpharma
April 04, 2019
A drug approved to treat a severe form of asthma dramatically improved the health of people with rare chronic immune disorders called hypereosinophilic syndromes (HES) in whom other treatments were ineffective or intolerable.
FDA approves new drug to treat travelers’ diarrhea firstwordpharma
November 19, 2018
The U.S. Food and Drug Administration today approved Aemcolo (rifamycin), an antibacterial drug indicated for the treatment of adult patients with travelers' diarrhea
Sonoma Pharmaceuticals Announces Pricing of Public Offering of Units firstwordpharma
November 19, 2018
Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA) today announced the pricing of a "best efforts" public offering of units consisting of one share of common stock
NW Bio Announces $5 Million Bridge Funding firstwordpharma
November 14, 2018
Northwest Biotherapeutics (OTCQB: NWBO) -- ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers
RadioMedix and Orano Med receive FDA Orphan Drug Designation for AlphaMedix for the treatment of neuroendocrine tumors firstwordpharma
November 14, 2018
Houston (TX U.S.), Courbevoie (France), Nov. 13, 2018 (GLOBE NEWSWIRE) -- RadioMedix Inc. (a Texas-based clinical stage biotechnology company) and Orano Med
Kymera Therapeutics Announces $65 Million Series B Financing to Advance Pipeline of Targeted Protein Degraders in Oncology and Immunology firstwordpharma
November 14, 2018
CAMBRIDGE, Mass., Nov. 13, 2018 /PRNewswire/ -- Kymera Therapeutics Inc., a biotechnology company pioneering targeted protein degradation to create breakthrough
NextCure Raises $93 Million in Series B Financing firstwordpharma
November 14, 2018
BELTSVILLE, Md.--(BUSINESS WIRE)-- NextCure Inc., a privately-held biopharmaceutical company discovering and developing the next generation of immunomedicines for cancer
AsclepiX Therapeutics Raises $5M in New Funding firstwordpharma
November 14, 2018
BALTIMORE--(BUSINESS WIRE)-- AsclepiX Therapeutics, Inc., a biopharmaceutical company focused on developing vital new therapies based on a novel peptide platform
AcelRx Pharmaceuticals Announces Pricing of Public Offering of Common Stock pharmafile
November 12, 2018
REDWOOD CITY, Calif., Nov. 9, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) today announced the pricing of its previously announced underwritten public
Harpoon Therapeutics Announces Closing of $70M Series C Financing pharmafile
November 12, 2018
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Harpoon Therapeutics, Inc. ("Harpoon"), a clinical-stage immunotherapy company developing a novel class of T cell engagers

Previous page 1 2 3 Next page